LB Pharmaceuticals Announces Equity Incentive for New Hire,Meeting Nasdaq Requirements
BOSTON,MA – November 12,2025 – LB Pharmaceuticals (Nasdaq: LBPH) today disclosed the grant of an inducement award to a newly appointed employee,as required by Nasdaq Listing Rule 5635(c)(4). The company reported the details in a press release issued this afternoon, signaling a strategic move to attract and retain key talent within the competitive life sciences sector.
This disclosure is especially significant for publicly traded companies like LB Pharmaceuticals, as Nasdaq mandates that equity awards granted to new hires-particularly those in executive positions-be publicly reported to ensure transparency and prevent potential conflicts of interest.The inducement award, consisting of stock options, is designed to align the new employee’s interests with those of LB Pharmaceuticals’ shareholders and incentivize long-term growth. The grant underscores LB Pharmaceuticals’ commitment to bolstering its team as it pursues ongoing research and development initiatives.
The inducement grant, approved by the company’s Compensation Commitee on November 12, 2025, consists of options to purchase 18,889 shares of LB Pharmaceuticals common stock. The exercise price for these options is $12.18 per share, equivalent to the closing price of the stock on November 12, 2025. The options are subject to the terms and conditions of the company’s 2021 Equity Incentive Plan and a corresponding stock option agreement.
The new employee, whose name was not disclosed in the release, is expected to contribute significantly to LB Pharmaceuticals’ pipeline development. The company anticipates the individual will commence employment on or before November 26, 2025. The grant is contingent upon the employee’s continued service with LB Pharmaceuticals.
Investors seeking further information are directed to contact JAllaire@LifeSciAdvisors.com.
